non-small cell lung cancer
Conditions
Interventions
Nab-paclitaxel 100mg/m2 on day 1,8,15 Cycles are repeated every three weeks.
Sponsors
Toho University Omori Medical Center
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1 Histologically or cytologically confirmed diagnosis of NSCLC. 2 Clinical Stage IIIB which curative radiotherapy is not indicated, IV or postoperative recurrence 3 No prior chemotherapy Adjuvant chemotherapy finished before 12 months or more from enrollment is permitted. Picibanil use for plural effusion is permitted. 4 No prior radiotherapy for primary lesions.(Palliative local radiation except for primary lesion is permitted.) 5 At least one measurable lesion 6 Age of 75 years or older 7 ECOG Performance status of 0-1 8 Adequate organ function 9 Life expectancy of at least 3 months 10 Written informed consent
Exclusion criteria
Exclusion criteria: 1)Active double cancer 2)Active infectious disease in need of systemic administration of anti-bacterial drugs 3)Uncontrolled psychiatric disease 4)History of Severe drug allergies. 5)Pleural effusion, cardiac effusion, or cardiac effusion necessitating treatment. 6)The continuous case that receive it from head to foot of the steroid 7)Severe concurrent disease
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression free survival | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall survival, response rate, frequency and the degree of the adverse event,QOL | — |
Countries
Japan
Contacts
Public ContactKazutoshi Isobe
Toho University Omori Medical Center Department of Respiratory Medicine
Outcome results
None listed